<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03275415</url>
  </required_header>
  <id_info>
    <org_study_id>N201705026</org_study_id>
    <nct_id>NCT03275415</nct_id>
  </id_info>
  <brief_title>Intratracheal Budesonide/Surfactant Prevents BPD</brief_title>
  <official_title>Routine Administration of Surfactant/Budesonide to Prevent BPD in VLBW With RDS-A Double Blind Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taipei Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Taipei Medical University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Taipei Veterans General Hospital, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mackay Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chung Shan Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>China Medical University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Taipei Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A double-blind study includes: 1) birth Wt 500-1499 gm, 2) respiratory distress shortly after
      birth and requires resuscitation 3) failure to NCPAP within 4 hrs after birth, defined as: a)
      FIO2 ≥ 0.30, pressure &gt; 5cmH2O b) severe retraction c) apnea d) PCO2 ≥ 60 mmHg. Exclusion
      criteria: 1) lethal cardiopulmonary status 2) severe congenital anomalies. Sample size will
      be determined based on a one-third (33%) improvement of the current incidence of BPD or death
      in the selected population (from 50%→33%), allowing a type I error 0.05, type II error 0.10
      (power 0.90), 182 infants in each group would be needed and 190 in each group would be a safe
      target number. The infants will be randomly assigned to control (C) (Curosurf/placebo) or
      intervention (I) (Curosurf/budesonide); given q. 12 hrs for a maximum of 3 doses unless the
      infant is extubated or require FIO2 &lt;30%. Appropriate amount of placebo will be used as it
      does not affect the biophysical property of curosurf (PAS abstract 2017 San Francisco)
      Primary outcome of study is death or BPD defined by NICHD criteria. Follow up study of
      neuromotor and cognitive function and pulmonary states will be done at 1-2 years of corrected
      age.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A double-blind study will be conducted in 7 tertiary centers. Inclusion criteria are: 1)
      birth Wt 500-1499 gm, 2) respiratory distress shortly after birth and requires resuscitation
      3) failure to NCPAP within 4 hrs after birth, defined as: a) FIO2 ≥ 0.30, pressure &gt; 5cmH2O
      b) severe retraction c) apnea d) PCO2 ≥ 60 mmHg. Exclusion criteria: 1) lethal
      cardiopulmonary status 2) severe congenital anomalies. Sample size will be determined based
      on a one-third (33%) improvement of the current incidence of BPD or death in the selected
      population (from 50%→33%), allowing a type I error 0.05, type II error 0.10 (power 0.90), 182
      infants in each group would be needed and 190 in each group would be a safe target number.
      The infants will be randomly assigned to control (C) (Curosurf/placebo) or intervention (I)
      (Curosurf/budesonide); given q. 12 hrs for a maximum of 3 doses unless the infant is
      extubated or require FIO2 &lt;30%. Appropriate amount of placebo will be used as it does not
      affect the biophysical property of curosurf (PAS abstract 2017 San Francisco) Primary outcome
      of study is death or BPD defined by NICHD criteria. Follow up study of neuromotor and
      cognitive function and pulmonary states will be done at 1-2 years of corrected age.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2017</start_date>
  <completion_date type="Anticipated">August 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a double blind randomized trial. The infants will be randomly assigned into 2 groups: Control (C) (curosurf + saline) and Intervention (I) (curosurf+ budesonide).</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>This is a double blind randomized trial. The infants will be randomly assigned into 2 groups: Control (C) (curosurf + saline) and Intervention (I) (curosurf+ budesonide).</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>incidence of death or BPD</measure>
    <time_frame>6 months</time_frame>
    <description>Primary outcome of study is death or BPD defined by NICHD criteria.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">380</enrollment>
  <condition>Respiratory Distress Syndrome</condition>
  <condition>Bronchopulmonary Dysplasia</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Curosurf + budesonide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Curosurf + saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>budesonide</intervention_name>
    <description>Intra-tracheal instillation of a combination of budesonide/surfactant in preterm infants with RDS to prevent BPD</description>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>pulmicort</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Intra-tracheal instillation of a combination of saline/surfactant in preterm infants with RDS to prevent BPD</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>sodium chloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1) birth Wt 500-1499 gm, 2) respiratory distress shortly after birth and requires
             resuscitation, 3) failure to NCPAP within 4 hrs after birth, defined as: a) FIO2 ≥
             0.30, pressure &gt; 5 cmH2O b) severe retraction c) apnea d) PCO2 ≥ 60 mmHg.

        Exclusion Criteria:

          -  1) lethal cardiopulmonary status, 2) severe congenital anomalies.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>4 Hours</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tsu F Yeh, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maternal Child Health Research Center, Taipei Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tsu F Yeh, M.D., Ph.D.</last_name>
    <phone>886-2-27361661</phone>
    <phone_ext>7213</phone_ext>
    <email>tfyeh@mail.ncku.edu.tw</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chung M. Chen, MD., PhD.</last_name>
    <phone>886-2-27372181</phone>
    <phone_ext>3715</phone_ext>
    <email>cmchen@tmu.edu.tw</email>
  </overall_contact_backup>
  <results_reference>
    <citation>Yeh TF, Chen CM, Wu SY, Husan Z, Li TC, Hsieh WS, Tsai CH, Lin HC. Intratracheal Administration of Budesonide/Surfactant to Prevent Bronchopulmonary Dysplasia. Am J Respir Crit Care Med. 2016 Jan 1;193(1):86-95. doi: 10.1164/rccm.201505-0861OC.</citation>
    <PMID>26351971</PMID>
  </results_reference>
  <results_reference>
    <citation>Yeh TF, Lin HC, Chang CH, Wu TS, Su BH, Li TC, Pyati S, Tsai CH. Early intratracheal instillation of budesonide using surfactant as a vehicle to prevent chronic lung disease in preterm infants: a pilot study. Pediatrics. 2008 May;121(5):e1310-8. doi: 10.1542/peds.2007-1973. Epub 2008 Apr 21.</citation>
    <PMID>18426851</PMID>
  </results_reference>
  <results_reference>
    <citation>Kuo HT, Lin HC, Tsai CH, Chouc IC, Yeh TF. A follow-up study of preterm infants given budesonide using surfactant as a vehicle to prevent chronic lung disease in preterm infants. J Pediatr. 2010 Apr;156(4):537-41. doi: 10.1016/j.jpeds.2009.10.049. Epub 2010 Feb 6.</citation>
    <PMID>20138301</PMID>
  </results_reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 5, 2017</study_first_submitted>
  <study_first_submitted_qc>September 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 7, 2017</study_first_posted>
  <last_update_submitted>September 6, 2017</last_update_submitted>
  <last_update_submitted_qc>September 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BPD</keyword>
  <keyword>surfactant</keyword>
  <keyword>budesonide</keyword>
  <keyword>respiratory distress syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Bronchopulmonary Dysplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Pulmonary Surfactants</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

